Risks
4 risks
Risk Intelligence
Geopolitical disruption impact on raw materials and freight
View Risks →Emcure Pharmaceuticals Ltd — Q4 FY26
Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and operating leverage.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and operating leverage. Domestic business was soft (+5.2%) due to Zuventus restructuring, but management confirmed April is back on track. Adjusted PAT grew 36% YoY to ₹279 crore. Guidance for FY27: low-to-mid teen revenue growth and 75-100 bps margin expansion, assuming stable macro conditions. Key growth levers include semaglutide partnership (Pista), biosimilar launches (Vasumarelic, Lenacapavir), and ADC pipeline. Risk: sustained geopolitical disruption could raise raw material costs and freight, pressuring margins if not passed through.
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
International Revenue Growth
₹1,493 Cr
+25.7% YoY
Strong growth across Europe (+35.8%), Canada (+28.6%), and emerging markets (+15.5%).
Field Productivity
₹7 Lakh/MR
+30% vs 2 years ago
Revenue per medical representative improved from ₹5.4 lakh to ₹7 lakh over two years.
R&D Spend
₹383.5 Cr
+50 bps YoY
R&D investment at 4.2% of revenue, up 50 bps YoY, focused on biosimilars and ADCs.
Zuventus Field Force
~40% of total MRs
Restructured in Q4
Zuventus represents ~40% of total MR count; restructuring caused higher attrition but recovery seen in April.
What Changed vs Last Quarter
NEW
Capex guidance: ₹400-425 crore for FY27
Capital expenditure for FY27 is expected to be in the range of ₹400-425 crore.
NEW
Semaglutide (Pista) steady growth in FY27
Aim for steady growth of the semaglutide brand Pista in FY27, leveraging competitive pricing and clinical differentiation.
UPDATED
FY27 revenue growth: low-to-mid teens
Management expects revenue growth in the low-to-mid teen percentage range for FY27, assuming stable macro conditions.
UPDATED
EBITDA margin expansion: 75-100 bps
Management committed to expanding EBITDA margins by 75-100 basis points in FY27, driven by operating leverage and productivity gains.
DROPPED
Net debt to be zero by end FY28
With strong cash flow generation, management expects to be net debt free by end FY28, barring any acquisitions.
DROPPED
Capex of ₹350-400 crore per year for next 2-3 years
Annual capital expenditure is expected to remain in the range of ₹350-400 crore, excluding acquisitions.
NEW RISK
Geopolitical disruption impact on raw materials and freight
Rising solvent prices, insurance, and freight costs due to Middle East conflict could pressure margins if not passed through.
NEW RISK
Zuventus restructuring may take longer to stabilize
Despite management's confidence, the acute nature of Zuventus portfolio means sales recovery may take longer than expected.
NEW RISK
Semaglutide generic competition and pricing pressure
Multiple generic entrants in the GLP-1 market could limit Pista's market share and revenue contribution.
NEW RISK
Currency volatility impacting international revenue
International business faces currency headwinds; guidance assumes average USD/INR of 92, but actual rates may vary.
RISK GONE
Product launch delays or regulatory hiccups
Delays in key product launches (e.g., Amphotericin B in Europe, lenacapavir) or regulatory issues could disrupt growth guidance.
RISK GONE
Gross margin pressure from mix shift
Faster international growth and in-licensed portfolios (Sanofi, semaglutide) are diluting gross margins, which could persist if mix continues.
RISK GONE
Competition in semaglutide and Amphotericin B
Fierce competition expected in GLP-1 and liposomal Amphotericin B markets; management acknowledges eventual competition but cites first-mover advantage.
RISK GONE
Geopolitical/macro risks
Geopolitical disturbances or macro headwinds could impact international operations, though management notes limited US exposure.
🤫 Topics management stopped discussing
Mentioned in Q1 FY26, Q3 FY26
Annual capital expenditure is expected to remain in the range of ₹350-400 crore, excluding acquisitions.
Fast read
Guidance and risk preview
Management expects revenue growth in the low-to-mid teen percentage range for FY27, assuming stable macro conditions.
Rising solvent prices, insurance, and freight costs due to Middle East conflict could pressure margins if not passed through.
View Risks →